Evolving utility of apremilast in dermatological disorders for off‐label indications
Sign Up to like & getrecommendations! Published in 2022 at "Clinical and Experimental Dermatology"
DOI: 10.1111/ced.15377
Abstract: Apremilast, a small molecule that acts by inhibition of the phosphodiesterase‐4 enzyme, has been approved by the US Food and Drug Administration for the management of psoriatic arthritis, plaque psoriasis and Behçet disease. The drug… read more here.
Keywords: label indications; apremilast; utility apremilast; dermatology ... See more keywords